Antihelminthics Market is Expected to Grow at a CAGR of ~ 8.92% from 2022 to 2030

Pune, India, May, 2023 /MRFR Press Release/- Market Research Future has a half cooked research report on the global Antihelminthics market.

Market Highlights

The global antihelminthics market is expected to grow at a CAGR of 8.92% during the forecast period 2022-2030 and is anticipated to reach USD 2,723.90 Million by 2030.

Antihelminthics are prescribed to kill parasites (helminthes). Common parasitic infestations include amebiasis, malaria, giardiasis, hookworm, pinworm, threadworm, whipworm and tapeworm infestations. The drugs function either by destroying the worms on contact or by paralyzing them, or by altering the permeability of their plasma membranes. According to World Health Organization (2014), over 1.5 billion people are infected with soil-transmitted helminths worldwide. Additionally, According to the latest report published by WHO, more than 880 million children are in need of treatment for these parasitic diseases. Increasing prevalence of parasitic diseases, rising demand for the treatment, and increasing number of patients drives the growth of the market. Moreover, changing lifestyle and increasing geriatric population have increased the probability of causing digestive tract infections, thus helps in driving the growth of the market. Additionally, the increasing need for the cost-effective treatment and increasing per capita income have fuelled the market growth. However, antihelminthics drugs are slightly toxic and some of the side effects are observed in some patients. This factors may restrain the growth of the market.

Regional Analysis

The Americas command the major share of the market owing to the large patient population, strong government support for research & development, growing prevalence of digestive diseases. According to the National Institute of Diabetes and Digestive and Kidney Diseases, over 135 million people are suffering from GI infection in America. Moreover, increasing geriatric population has fuelled the growth of the market.  

Europe holds the second position in the global antihelminthics market followed by Asia Pacific.  The growth of the European market is majorly attributed to the increasing geriatric population, government support, and well-developed healthcare sector. Asia Pacific is the fastest growing antihelminthics market. China, and India are the key contributors to the market growth due to huge patient population, rapidly growing economy to support the population, increasing healthcare expenditure, and huge population base.

The UAE, Saudi Arabia, and Kuwait are expected to drive the Middle East & African market. The Middle East & Africa holds the least share of the global market due to limited availability of medical facilities and poor economic condition in African region. However the growth of the Africa market is high due to presence of opportunities for the development of this market.

Explore In-depth Details: Antihelminthics Market Research Report

Segmentation

The global antihelminthics market has been segmented on the basis of types, application, and end user.

On the basis of types, the market is segmented into benzimidazoles, abamectin, salicylanilides, praziquantel and others. Benzimidazoles is further segmented into albendazole, mebendazole, benzimidazoles, thiabendazole, and others. Salicylanilides is further segmented into niclosamide, oxyclozanide, rafoxanide, and others.

On the basis of applications, the market is segmented into schistosomiasis, fasciolasis, filariasis, angiostrongylosis, ascariasis, giardiasis and others.

On the basis of end user, the market is segmented into hospitals, clinics, and others.

Key Players

Some of key the players in the market are Abbott (US), Novartis AG (Switzerland), ZEISS International (Germany), Johnson & Johnson Services, Inc (US), Sanofi (US), Merck & Co., Inc. (US), GlaxoSmithKline plc (US), Astellas Pharma Inc. (Japan), Bayer AG (Germany), Mentis Pharma Ltd. (India), Pfizer Inc. (US), Sanofi (France), ALLERGAN (Ireland), and AstraZeneca (UK).